Global Neuroblastoma Chemotherapy Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Neuroblastoma Chemotherapy Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Neuroblastoma, a common malignant tumor in children, relies significantly on chemotherapy as part of its comprehensive treatment. Several chemotherapy drugs targeting neuroblastoma are already available in the market, effectively controlling disease progression by interfering with the growth and division of tumor cells. The market size has been gradually expanding due to increasing diagnosis rates and advancements in medical technology, leading to consistent growth in sales of chemotherapy drugs for pediatric neuroblastoma. Looking ahead, with the development of personalized treatments and targeted therapies, neuroblastoma chemotherapy drugs are poised to become more precise in targeting tumor cells, minimizing side effects, and enhancing therapeutic efficacy, thereby offering greater hope for affected children.

The Global Info Research report includes an overview of the development of the Neuroblastoma Chemotherapy Drugs industry chain, the market status of Hospital (Cyclophosphamide, Cisplatin or Carboplatin), Clinic (Cyclophosphamide, Cisplatin or Carboplatin), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neuroblastoma Chemotherapy Drugs.

Regionally, the report analyzes the Neuroblastoma Chemotherapy Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neuroblastoma Chemotherapy Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Neuroblastoma Chemotherapy Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neuroblastoma Chemotherapy Drugs industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Cyclophosphamide, Cisplatin or Carboplatin).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neuroblastoma Chemotherapy Drugs market.

Regional Analysis: The report involves examining the Neuroblastoma Chemotherapy Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neuroblastoma Chemotherapy Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Neuroblastoma Chemotherapy Drugs:
Company Analysis: Report covers individual Neuroblastoma Chemotherapy Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neuroblastoma Chemotherapy Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

Technology Analysis: Report covers specific technologies relevant to Neuroblastoma Chemotherapy Drugs. It assesses the current state, advancements, and potential future developments in Neuroblastoma Chemotherapy Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neuroblastoma Chemotherapy Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Neuroblastoma Chemotherapy Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
    Cyclophosphamide
    Cisplatin or Carboplatin
    Vincristine
    Doxorubicin (Adriamycin)
    Etoposide
    Other

Market segment by Application
    Hospital
    Clinic
    Other

Major players covered
    Baxter Healthcare
    Ingenus Pharmaceuticals
    ANI Pharmaceuticals
    Teva Pharmaceuticals
    Qilu Pharmaceutical
    Pfizer
    Hikma Pharmaceuticals
    Fresenius Kabi
    Accord Healthcare
    Viatris

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroblastoma Chemotherapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neuroblastoma Chemotherapy Drugs, with price, sales, revenue and global market share of Neuroblastoma Chemotherapy Drugs from 2019 to 2024.
Chapter 3, the Neuroblastoma Chemotherapy Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Chemotherapy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Neuroblastoma Chemotherapy Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neuroblastoma Chemotherapy Drugs.
Chapter 14 and 15, to describe Neuroblastoma Chemotherapy Drugs sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neuroblastoma Chemotherapy Drugs
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Cyclophosphamide
        1.3.3 Cisplatin or Carboplatin
        1.3.4 Vincristine
        1.3.5 Doxorubicin (Adriamycin)
        1.3.6 Etoposide
        1.3.7 Other
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 Other
    1.5 Global Neuroblastoma Chemotherapy Drugs Market Size & Forecast
        1.5.1 Global Neuroblastoma Chemotherapy Drugs Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Neuroblastoma Chemotherapy Drugs Sales Quantity (2019-2030)
        1.5.3 Global Neuroblastoma Chemotherapy Drugs Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Baxter Healthcare
        2.1.1 Baxter Healthcare Details
        2.1.2 Baxter Healthcare Major Business
        2.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
        2.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Baxter Healthcare Recent Developments/Updates
    2.2 Ingenus Pharmaceuticals
        2.2.1 Ingenus Pharmaceuticals Details
        2.2.2 Ingenus Pharmaceuticals Major Business
        2.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        2.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
    2.3 ANI Pharmaceuticals
        2.3.1 ANI Pharmaceuticals Details
        2.3.2 ANI Pharmaceuticals Major Business
        2.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        2.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 ANI Pharmaceuticals Recent Developments/Updates
    2.4 Teva Pharmaceuticals
        2.4.1 Teva Pharmaceuticals Details
        2.4.2 Teva Pharmaceuticals Major Business
        2.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        2.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Teva Pharmaceuticals Recent Developments/Updates
    2.5 Qilu Pharmaceutical
        2.5.1 Qilu Pharmaceutical Details
        2.5.2 Qilu Pharmaceutical Major Business
        2.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
        2.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Qilu Pharmaceutical Recent Developments/Updates
    2.6 Pfizer
        2.6.1 Pfizer Details
        2.6.2 Pfizer Major Business
        2.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
        2.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Pfizer Recent Developments/Updates
    2.7 Hikma Pharmaceuticals
        2.7.1 Hikma Pharmaceuticals Details
        2.7.2 Hikma Pharmaceuticals Major Business
        2.7.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
        2.7.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Hikma Pharmaceuticals Recent Developments/Updates
    2.8 Fresenius Kabi
        2.8.1 Fresenius Kabi Details
        2.8.2 Fresenius Kabi Major Business
        2.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
        2.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Fresenius Kabi Recent Developments/Updates
    2.9 Accord Healthcare
        2.9.1 Accord Healthcare Details
        2.9.2 Accord Healthcare Major Business
        2.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
        2.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Accord Healthcare Recent Developments/Updates
    2.10 Viatris
        2.10.1 Viatris Details
        2.10.2 Viatris Major Business
        2.10.3 Viatris Neuroblastoma Chemotherapy Drugs Product and Services
        2.10.4 Viatris Neuroblastoma Chemotherapy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Viatris Recent Developments/Updates

3 Competitive Environment: Neuroblastoma Chemotherapy Drugs by Manufacturer
    3.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2019-2024)
    3.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Neuroblastoma Chemotherapy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2023
        3.4.2 Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer Market Share in 2023
    3.5 Neuroblastoma Chemotherapy Drugs Market: Overall Company Footprint Analysis
        3.5.1 Neuroblastoma Chemotherapy Drugs Market: Region Footprint
        3.5.2 Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
        3.5.3 Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Neuroblastoma Chemotherapy Drugs Market Size by Region
        4.1.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2019-2030)
        4.1.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2019-2030)
        4.1.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2019-2030)
    4.2 North America Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030)
    4.3 Europe Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030)
    4.4 Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030)
    4.5 South America Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030)
    4.6 Middle East and Africa Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2030)
    5.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2019-2030)
    5.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2030)
    6.2 Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2019-2030)
    6.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2019-2030)

7 North America
    7.1 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2030)
    7.2 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2030)
    7.3 North America Neuroblastoma Chemotherapy Drugs Market Size by Country
        7.3.1 North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2030)
        7.3.2 North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2030)
    8.2 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2030)
    8.3 Europe Neuroblastoma Chemotherapy Drugs Market Size by Country
        8.3.1 Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2030)
        8.3.2 Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Neuroblastoma Chemotherapy Drugs Market Size by Region
        9.3.1 Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2030)
    10.2 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2030)
    10.3 South America Neuroblastoma Chemotherapy Drugs Market Size by Country
        10.3.1 South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2030)
        10.3.2 South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Neuroblastoma Chemotherapy Drugs Market Size by Country
        11.3.1 Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Neuroblastoma Chemotherapy Drugs Market Drivers
    12.2 Neuroblastoma Chemotherapy Drugs Market Restraints
    12.3 Neuroblastoma Chemotherapy Drugs Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Neuroblastoma Chemotherapy Drugs and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Neuroblastoma Chemotherapy Drugs
    13.3 Neuroblastoma Chemotherapy Drugs Production Process
    13.4 Neuroblastoma Chemotherapy Drugs Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Neuroblastoma Chemotherapy Drugs Typical Distributors
    14.3 Neuroblastoma Chemotherapy Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
    Table 4. Baxter Healthcare Major Business
    Table 5. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
    Table 6. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Baxter Healthcare Recent Developments/Updates
    Table 8. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 9. Ingenus Pharmaceuticals Major Business
    Table 10. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 11. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. Ingenus Pharmaceuticals Recent Developments/Updates
    Table 13. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 14. ANI Pharmaceuticals Major Business
    Table 15. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 16. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. ANI Pharmaceuticals Recent Developments/Updates
    Table 18. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 19. Teva Pharmaceuticals Major Business
    Table 20. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 21. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. Teva Pharmaceuticals Recent Developments/Updates
    Table 23. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 24. Qilu Pharmaceutical Major Business
    Table 25. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product and Services
    Table 26. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. Qilu Pharmaceutical Recent Developments/Updates
    Table 28. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 29. Pfizer Major Business
    Table 30. Pfizer Neuroblastoma Chemotherapy Drugs Product and Services
    Table 31. Pfizer Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. Pfizer Recent Developments/Updates
    Table 33. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 34. Hikma Pharmaceuticals Major Business
    Table 35. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product and Services
    Table 36. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 37. Hikma Pharmaceuticals Recent Developments/Updates
    Table 38. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
    Table 39. Fresenius Kabi Major Business
    Table 40. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product and Services
    Table 41. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 42. Fresenius Kabi Recent Developments/Updates
    Table 43. Accord Healthcare Basic Information, Manufacturing Base and Competitors
    Table 44. Accord Healthcare Major Business
    Table 45. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product and Services
    Table 46. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 47. Accord Healthcare Recent Developments/Updates
    Table 48. Viatris Basic Information, Manufacturing Base and Competitors
    Table 49. Viatris Major Business
    Table 50. Viatris Neuroblastoma Chemotherapy Drugs Product and Services
    Table 51. Viatris Neuroblastoma Chemotherapy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 52. Viatris Recent Developments/Updates
    Table 53. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 54. Global Neuroblastoma Chemotherapy Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 55. Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 56. Market Position of Manufacturers in Neuroblastoma Chemotherapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 57. Head Office and Neuroblastoma Chemotherapy Drugs Production Site of Key Manufacturer
    Table 58. Neuroblastoma Chemotherapy Drugs Market: Company Product Type Footprint
    Table 59. Neuroblastoma Chemotherapy Drugs Market: Company Product Application Footprint
    Table 60. Neuroblastoma Chemotherapy Drugs New Market Entrants and Barriers to Market Entry
    Table 61. Neuroblastoma Chemotherapy Drugs Mergers, Acquisition, Agreements, and Collaborations
    Table 62. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2019-2024) & (K Units)
    Table 63. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2025-2030) & (K Units)
    Table 64. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 65. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 66. Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2019-2024) & (US$/Unit)
    Table 67. Global Neuroblastoma Chemotherapy Drugs Average Price by Region (2025-2030) & (US$/Unit)
    Table 68. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 69. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 70. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
    Table 71. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
    Table 72. Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2019-2024) & (US$/Unit)
    Table 73. Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2025-2030) & (US$/Unit)
    Table 74. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 75. Global Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 76. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
    Table 77. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
    Table 78. Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2019-2024) & (US$/Unit)
    Table 79. Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2025-2030) & (US$/Unit)
    Table 80. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 81. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 82. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 83. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 84. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2024) & (K Units)
    Table 85. North America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2025-2030) & (K Units)
    Table 86. North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 87. North America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 88. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 89. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 90. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 91. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 92. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2024) & (K Units)
    Table 93. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2025-2030) & (K Units)
    Table 94. Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 95. Europe Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 96. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 97. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 98. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 99. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 100. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2019-2024) & (K Units)
    Table 101. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2025-2030) & (K Units)
    Table 102. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 103. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 104. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 105. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 106. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 107. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 108. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2019-2024) & (K Units)
    Table 109. South America Neuroblastoma Chemotherapy Drugs Sales Quantity by Country (2025-2030) & (K Units)
    Table 110. South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 111. South America Neuroblastoma Chemotherapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 112. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 113. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 114. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 115. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 116. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2019-2024) & (K Units)
    Table 117. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity by Region (2025-2030) & (K Units)
    Table 118. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 119. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 120. Neuroblastoma Chemotherapy Drugs Raw Material
    Table 121. Key Manufacturers of Neuroblastoma Chemotherapy Drugs Raw Materials
    Table 122. Neuroblastoma Chemotherapy Drugs Typical Distributors
    Table 123. Neuroblastoma Chemotherapy Drugs Typical Customers
List of Figures
    Figure 1. Neuroblastoma Chemotherapy Drugs Picture
    Figure 2. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Type in 2023
    Figure 4. Cyclophosphamide Examples
    Figure 5. Cisplatin or Carboplatin Examples
    Figure 6. Vincristine Examples
    Figure 7. Doxorubicin (Adriamycin) Examples
    Figure 8. Etoposide Examples
    Figure 9. Other Examples
    Figure 10. Global Neuroblastoma Chemotherapy Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 11. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Application in 2023
    Figure 12. Hospital Examples
    Figure 13. Clinic Examples
    Figure 14. Other Examples
    Figure 15. Global Neuroblastoma Chemotherapy Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 16. Global Neuroblastoma Chemotherapy Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 17. Global Neuroblastoma Chemotherapy Drugs Sales Quantity (2019-2030) & (K Units)
    Figure 18. Global Neuroblastoma Chemotherapy Drugs Average Price (2019-2030) & (US$/Unit)
    Figure 19. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Manufacturer in 2023
    Figure 20. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Manufacturer in 2023
    Figure 21. Producer Shipments of Neuroblastoma Chemotherapy Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 22. Top 3 Neuroblastoma Chemotherapy Drugs Manufacturer (Consumption Value) Market Share in 2023
    Figure 23. Top 6 Neuroblastoma Chemotherapy Drugs Manufacturer (Consumption Value) Market Share in 2023
    Figure 24. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 25. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 26. North America Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 27. Europe Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 28. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 29. South America Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 30. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 31. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 32. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Type (2019-2030)
    Figure 33. Global Neuroblastoma Chemotherapy Drugs Average Price by Type (2019-2030) & (US$/Unit)
    Figure 34. Global Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 35. Global Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Application (2019-2030)
    Figure 36. Global Neuroblastoma Chemotherapy Drugs Average Price by Application (2019-2030) & (US$/Unit)
    Figure 37. North America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 38. North America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 39. North America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 40. North America Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 41. United States Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 42. Canada Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 43. Mexico Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 44. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 45. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 46. Europe Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 47. Europe Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 48. Germany Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. France Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 50. United Kingdom Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 51. Russia Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 52. Italy Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 53. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 54. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 55. Asia-Pacific Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 56. Asia-Pacific Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 57. China Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Japan Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. Korea Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 60. India Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 61. Southeast Asia Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 62. Australia Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 63. South America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 64. South America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 65. South America Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 66. South America Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 67. Brazil Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 68. Argentina Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 69. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 70. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 71. Middle East & Africa Neuroblastoma Chemotherapy Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 72. Middle East & Africa Neuroblastoma Chemotherapy Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 73. Turkey Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 74. Egypt Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 75. Saudi Arabia Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 76. South Africa Neuroblastoma Chemotherapy Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 77. Neuroblastoma Chemotherapy Drugs Market Drivers
    Figure 78. Neuroblastoma Chemotherapy Drugs Market Restraints
    Figure 79. Neuroblastoma Chemotherapy Drugs Market Trends
    Figure 80. Porters Five Forces Analysis
    Figure 81. Manufacturing Cost Structure Analysis of Neuroblastoma Chemotherapy Drugs in 2023
    Figure 82. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
    Figure 83. Neuroblastoma Chemotherapy Drugs Industrial Chain
    Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 85. Direct Channel Pros & Cons
    Figure 86. Indirect Channel Pros & Cons
    Figure 87. Methodology
    Figure 88. Research Process and Data Source

Companies Mentioned

Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris